News
NRSN
0.4531
+2.26%
0.0100
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts
TipRanks · 2d ago
NeuroSense Issues CEO Letter to Shareholders
PR Newswire · 2d ago
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)
TipRanks · 4d ago
Weekly Report: what happened at NRSN last week (0803-0807)?
Weekly Report · 5d ago
NeuroSense sees December 2026 as filing date for NDS for PrimeC
TipRanks · 08/06 15:35
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
PR Newswire · 08/06 15:29
Weekly Report: what happened at NRSN last week (0727-0731)?
Weekly Report · 08/03 09:49
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective
TipRanks · 07/31 20:48
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split
TipRanks · 07/31 20:48
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/28 09:01
Weekly Report: what happened at NRSN last week (0720-0724)?
Weekly Report · 07/27 09:52
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS
TipRanks · 07/22 12:56
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting
Benzinga · 07/22 12:38
NeuroSense to file NDS to Health Canada for PrimeC for treatment of ALS
TipRanks · 07/22 12:35
Weekly Report: what happened at NRSN last week (0713-0717)?
Weekly Report · 07/20 09:49
Weekly Report: what happened at NRSN last week (0706-0710)?
Weekly Report · 07/13 09:51
Weekly Report: what happened at NRSN last week (0629-0703)?
Weekly Report · 07/06 09:53
Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial
TipRanks · 07/02 13:05
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3
TipRanks · 06/29 13:57
NeuroSense Says Phase 2b ALS Study Meets Primary Endpoint
NASDAQ · 06/29 13:49
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions.